Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Best Pract Res Clin Rheumatol. 2011 Oct;25(5):735–747. doi: 10.1016/j.berh.2011.10.020

Table 2.

Medical management of hyperphosphatemic tumoral calcinosis.

Treatment Mechanism Urinary phosphate Serum phosphate Serum calcium Serum 1,25D Tumoral calcinosis lesions
Dietary phosphate restriction Decrease phosphate load ↓ ↓ ↔ ↑ ↔ ↓ ↔
Phosphate binders Decrease phosphate load ↓ ↓ ↔ ↑ ↔ ↓ ↔
Acetazolamide Increase phosphate excretion ↑ ↓ ↔ ↔ ↓ ↔
Calcitonin Increase phosphate excretion ↑ ↓in TC (but↑ in XLH) ↔ ↓ ↑ ↓ ↔